Today's Low
₹ 330.35
Today's High
₹ 343.00
52 Weeks Low
₹ 251.80
52 Weeks High
₹ 418.90
Lower
₹ 266.70
Upper
₹ 400.00
Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 172.2 | 116.3 | 120.5 | 96.3 | 97.6 | 94.6 | 110.1 | 101.0 | 95.8 | 91.3 | 86.5 | 90.9 |
Total Non-Current Assets | 30.4 | 55.1 | 43.7 | 52.4 | 38.2 | 35.2 | 32.5 | 58.3 | 58.4 | 64.9 | 66.5 | 65.2 |
Total Assets | 202.6 | 171.4 | 164.2 | 148.7 | 135.8 | 129.8 | 142.6 | 159.3 | 154.2 | 156.3 | 153.0 | 156.1 |
Total Current Liabilities | 35.2 | 34.1 | 40.4 | 34.6 | 28.2 | 28.6 | 29.4 | 57.3 | 55.2 | 53.6 | 50.1 | 53.4 |
Total Non-Current Liabilities | 8.5 | 4.5 | 1.9 | 3.1 | 3.1 | 3.2 | 3.3 | 3.6 | 3.6 | 4.1 | 4.5 | 4.3 |
Shareholder's Funds | 158.9 | 132.8 | 121.9 | 111.0 | 104.5 | 98.1 | 109.9 | 98.4 | 95.4 | 98.6 | 98.4 | 98.5 |
Total Liabilities | 202.6 | 171.4 | 164.2 | 148.7 | 135.8 | 129.8 | 142.6 | 159.3 | 154.2 | 156.3 | 153.0 | 156.1 |
The Industry Debt to Equity Ratio stands at 0.20, vs the Debt to Equity Ratio of 0.00, which results in a Positive aspect.
The Industry Price to BV stands at 6.01, vs the Price to BV of 4.70, which results in a Negative aspect.
The Industry Current Ratio stands at 2.53, vs the Current Ratio of 4.89, which results in a Positive aspect.
The Industry Quick Ratio stands at 1.77, vs the Quick Ratio of 4.31, which results in a Positive aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 236.7 | 217.6 | 188.0 | 158.6 | 166.8 | 126.5 | 143.9 | 143.5 | 138.2 | 143.9 | 166.5 | 176.5 |
Total Expenditure | 202.6 | 192.6 | 168.9 | 150.0 | 157.5 | 137.6 | 138.1 | 131.7 | 129.4 | 133.2 | 156.4 | 159.9 |
Operating Profit(Excl OI) | 39.9 | 28.5 | 23.5 | 11.1 | 10.8 | -10.7 | 6.2 | 12.5 | 8.8 | 10.7 | 10.4 | 17.0 |
Add: Other Income | 5.7 | 3.4 | 4.4 | 2.5 | 1.4 | 0.5 | 0.5 | 0.7 | 0.1 | 0.1 | 0.3 | 0.4 |
Operating Profit | 39.9 | 28.5 | 23.5 | 11.1 | 10.8 | -10.7 | 6.2 | 12.5 | 8.8 | 10.7 | 10.4 | 17.0 |
Less: Interest | 0.4 | 0.3 | 0.5 | 0.5 | 0.8 | 0.7 | 2.6 | 5.3 | 4.5 | 5.4 | 5.1 | 4.4 |
PBDT | 39.5 | 28.2 | 23.0 | 10.5 | 10.0 | -11.3 | 3.6 | 7.2 | 4.4 | 5.4 | 5.2 | 12.6 |
Less: Depreciation Amortization | 1.2 | 1.5 | 1.1 | 1.1 | 1.0 | 0.3 | 2.0 | 3.1 | 2.7 | 2.8 | 2.7 | 2.5 |
PBT & Exceptional Items | 38.3 | 26.6 | 21.9 | 9.4 | 9.0 | -11.6 | 1.6 | 4.1 | 1.7 | 2.5 | 2.5 | 10.1 |
Less: Exceptional Income Expenses | -3.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | 34.8 | 26.6 | 21.9 | 9.4 | 9.0 | -11.6 | 14.4 | 4.1 | 1.7 | 2.5 | 2.5 | 10.1 |
Less: Taxation | 8.1 | 7.8 | 4.8 | 1.5 | 1.8 | -0.1 | 2.5 | 0.8 | 0.5 | 0.4 | 0.7 | 2.6 |
Profit After Tax | 26.7 | 18.9 | 17.1 | 7.9 | 7.2 | -11.6 | 11.9 | 3.3 | 1.2 | 2.1 | 1.8 | 7.5 |
Earnings Per Share | 1.0 | 0.7 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry PAT Margin stands at 9.68, vs the PAT Margin of 10.39, which results in a Positive aspect.
The Industry PAT Growth stands at 41.10, vs the PAT Growth of 41.72, which results in a Positive aspect.
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 1.57, which results in a Positive aspect.
The Industry PE Ratio stands at 42.40, vs the PE Ratio of 34.35, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 34.8 | 26.6 | 21.9 | 9.4 | 9.0 | -11.6 | 14.4 | 4.1 | 1.7 | 2.5 | 2.5 | 10.1 |
Tax Paid | -7.3 | -6.9 | -3.2 | -1.8 | 1.9 | 0.0 | -2.9 | -0.8 | -0.3 | -0.5 | -0.5 | -2.0 |
Adjustment | 9.2 | -1.4 | -2.1 | -0.6 | 0.3 | 1.3 | -8.6 | 7.7 | 7.1 | 8.1 | 7.5 | 6.5 |
Changes In Working Capital | 34.8 | 26.6 | 21.9 | 9.4 | 9.0 | -11.6 | 14.4 | 4.1 | 1.7 | 2.5 | 2.5 | 10.1 |
Cash Flow after changes in Working Capital | 53.9 | 13.8 | 31.4 | 13.7 | 29.0 | -1.6 | -0.4 | 9.9 | 4.6 | 8.0 | 12.6 | 9.1 |
Cash Flow from Operating Activities | 46.7 | 6.9 | 28.2 | 11.9 | 30.9 | -1.6 | -3.2 | 9.0 | 4.3 | 7.5 | 12.0 | 7.1 |
Cash Flow from Investing Activities | -57.7 | -25.8 | -2.3 | -11.1 | -0.8 | -3.4 | 41.3 | -2.1 | -0.5 | -1.2 | -3.4 | -4.9 |
Cash Flow from Financing Activities | -0.5 | -17.6 | -6.8 | -1.8 | -6.1 | -0.6 | -33.5 | -6.4 | -1.4 | -4.0 | -8.2 | 0.4 |
Net Cash Inflow / Outflow | -11.5 | -36.4 | 19.1 | -1.0 | 24.0 | -5.5 | 4.5 | 0.5 | 2.4 | 2.3 | 0.5 | 2.6 |
Opening Cash & Cash Equivalents | 22.5 | 58.9 | 39.8 | 40.8 | 14.5 | 20.1 | 15.5 | 15.0 | 12.6 | 10.3 | 9.9 | 7.3 |
Closing Cash & Cash Equivalent | 11.1 | 22.5 | 58.9 | 39.8 | 38.5 | 14.5 | 20.1 | 15.5 | 15.0 | 12.6 | 10.3 | 9.9 |
The Industry PCF RATIO stands at 27.04, vs the PCF RATIO of 16.28, which results in a Negative aspect.
The Industry PFCF Ratio stands at 37.73, vs the PFCF Ratio of 20.26, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 472.3 | 578.3 | 601.5 | 554.5 | 601.4 | 605.3 | 606.0 | 521.4 | 544.7 | 594.9 | 600.0 | 428.4 | 571.0 | 563.5 | 316.5 | 295.2 |
Total Income | 497.6 | 601.0 | 621.5 | 580.1 | 618.8 | 616.5 | 609.1 | 524.1 | 564.3 | 597.7 | 608.2 | 455.0 | 576.4 | 567.7 | 324.4 | 302.8 |
Total Expenditure | 438.4 | 494.6 | 515.2 | 500.1 | 515.1 | 476.3 | 541.8 | 515.1 | 488.6 | 492.1 | 507.2 | 377.2 | 506.2 | 515.2 | 290.0 | 283.0 |
PBIDT (Excl OI) | 34.0 | 83.7 | 86.4 | 54.4 | 86.3 | 129.0 | 64.2 | 6.3 | 56.1 | 102.8 | 92.8 | 51.2 | 64.8 | 48.3 | 26.5 | 12.2 |
Other Income | 25.2 | 22.7 | 20.0 | 25.6 | 17.4 | 11.2 | 3.1 | 2.8 | 19.5 | 2.9 | 8.2 | 26.6 | 5.4 | 4.1 | 7.8 | 7.6 |
Operating Profit | 59.2 | 106.4 | 106.3 | 80.0 | 103.8 | 140.2 | 67.3 | 9.0 | 75.7 | 105.7 | 101.0 | 77.8 | 70.2 | 52.5 | 34.3 | 19.8 |
Interest | 2.3 | 2.2 | 1.5 | 2.0 | 1.8 | 0.3 | 0.1 | 0.6 | 0.6 | 0.6 | 1.1 | 1.3 | 1.4 | 1.2 | 1.3 | 1.5 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -58.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 56.9 | 104.2 | 104.8 | 78.0 | 102.0 | 140.0 | 9.1 | 8.4 | 75.1 | 105.0 | 99.9 | 76.5 | 68.8 | 51.3 | 33.0 | 18.4 |
Depreciation | 4.1 | 4.6 | 3.9 | 4.8 | 3.3 | 2.0 | 1.9 | 6.5 | 3.7 | 2.3 | 2.8 | 2.6 | 2.7 | 2.8 | 2.8 | 3.2 |
Profit Before Tax | 52.8 | 99.6 | 100.9 | 73.2 | 98.7 | 137.9 | 7.2 | 2.0 | 71.4 | 102.8 | 97.1 | 73.8 | 66.1 | 48.6 | 30.3 | 15.2 |
Tax | 13.2 | 24.9 | 26.1 | 17.2 | 20.8 | 33.8 | 3.5 | 1.8 | 17.3 | 29.7 | 28.6 | 22.8 | 11.8 | 8.5 | 5.1 | -0.4 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 39.6 | 74.7 | 74.8 | 56.0 | 77.9 | 104.1 | 3.7 | 0.2 | 54.1 | 73.1 | 68.5 | 51.0 | 54.3 | 40.1 | 25.2 | 15.5 |
Net Profit | 39.6 | 74.7 | 74.8 | 56.0 | 77.9 | 104.1 | 3.7 | 0.2 | 54.1 | 73.1 | 68.5 | 51.0 | 54.3 | 40.1 | 25.2 | 15.5 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 131.4 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 | 131.0 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 1.5 | 2.8 | 2.9 | 2.1 | 3.0 | 4.0 | 0.1 | 0.0 | 2.1 | 2.8 | 2.6 | 2.0 | 2.1 | 1.5 | 1.0 | 0.6 |
Operating Profit Margin | 12.5 | 18.4 | 17.7 | 14.4 | 17.3 | 23.2 | 11.1 | 1.7 | 13.9 | 17.8 | 16.8 | 18.2 | 12.3 | 9.3 | 10.8 | 6.7 |
Net Profit Margin | 8.4 | 12.9 | 12.4 | 10.1 | 12.9 | 17.2 | 0.6 | 0.0 | 9.9 | 12.3 | 11.4 | 11.9 | 9.5 | 7.1 | 8.0 | 5.3 |
The Industry Net Sales Growth stands at 10.00, vs the Net Sales Growth of 8.79, which results in a Negative aspect.
The Industry Mcap Growth stands at -4.23, vs the Mcap Growth of -7.56, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 374.85 | 387.81 | 352.16 |
R3 | 365.23 | 367.03 | 347.85 |
R2 | 355.62 | 356.51 | 346.42 |
R1 | 349.58 | 351.38 | 344.98 |
Pivot | 339.97 | 340.86 | 339.97 |
S1 | 333.93 | 335.73 | 342.12 |
S2 | 324.32 | 325.21 | 340.68 |
S3 | 318.28 | 320.08 | 339.25 |
S4 | 312.25 | 293.91 | 334.94 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
82.89
Bearish
RSI
53.92
Neutral
ROC
11.99
Bullish
UltimateOscillator
61.57
Neutral
Williams Indicator
-9.24
Bearish
CCI Indicator
161.36
Bearish
MACD
-2,693.52
Bearish
Stochastic Indicator
86.67
Neutral
ATR
14.64
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|---|---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|---|---|---|
21-08-2023 | 5.00 | 100 | Final |
29-10-2021 | 4.00 | 80 | Interim |
22-09-2021 | 1.00 | 20 | Final |
Date Of Conduct | Board Meeting Details |
---|---|
02-02-2024 | Quarterly Results |
03-11-2023 | Quarterly Results |
02-08-2023 | Quarterly Results |
23-05-2023 | Dividend & Audited Results |
08-02-2023 | Quarterly Results |
09-11-2022 | Quarterly Results |
09-08-2022 | Quarterly Results |
30-05-2022 | Audited Results & Quarterly Results |
13-05-2022 | Inter alia, to consider and approve the alteration in AOA and other routine matters. |
11-02-2022 | Quarterly Results |
27-01-2022 | JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2022 ,inter alia, to consider and approve unaudited financial results for the quarter and nine months ended 31.December.2021. |
19-10-2021 | Quarterly Results & Interim Dividend |
13-08-2021 | Quarterly Results |
30-06-2021 | A.G.M. & Dividend & Audited Results |
25-05-2021 | Inter alia, to consider and approve investment in the associate company along with other routine matters. |